Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis.

bone sarcoma chemotherapy infusional ifosfamide soft-tissue sarcoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Nov 2020
Historique:
received: 21 10 2020
revised: 08 11 2020
accepted: 11 11 2020
entrez: 20 11 2020
pubmed: 21 11 2020
medline: 21 11 2020
Statut: epublish

Résumé

Ifosfamide is used to treat soft-tissue sarcoma (STS) and bone sarcoma (BS), with improved efficacy at doses above 9 g/m

Identifiants

pubmed: 33212978
pii: cancers12113408
doi: 10.3390/cancers12113408
pmc: PMC7698576
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Pediatr Blood Cancer. 2009 May;52(5):581-4
pubmed: 19142994
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Oncologist. 2007 Nov;12(11):1351-60
pubmed: 18055856
Pediatr Blood Cancer. 2010 Oct;55(4):617-20
pubmed: 20589638
Ann Surg Oncol. 1999 Jun;6(4):389-94
pubmed: 10379861
Ann Oncol. 1997 Nov;8(11):1159-62
pubmed: 9426338
Clin Sarcoma Res. 2014 Nov 22;4(1):16
pubmed: 25628856
Curr Opin Oncol. 2011 Jul;23(4):373-8
pubmed: 21552124
J Cancer Res Clin Oncol. 1997;123(4):227-31
pubmed: 9177496
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
J Oncol Pract. 2016 Mar;12(3):208-16
pubmed: 26962160
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
J Oncol Pharm Pract. 2020 Oct;26(7):1715-1720
pubmed: 32594844
Sarcoma. 2013;2013:868973
pubmed: 24369450
Cells. 2020 Oct 31;9(11):
pubmed: 33142760
Am J Clin Oncol. 2018 Feb;41(2):147-151
pubmed: 26523439
Radiology. 2009 May;251(2):447-56
pubmed: 19261927
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
Clin Kidney J. 2020 Apr 17;13(4):500-503
pubmed: 32897272
Lancet. 1990 Jan 20;335(8682):175
pubmed: 1967471
Oncology. 2011;80(3-4):257-61
pubmed: 21734417
Clin Pharm. 1990 Mar;9(3):179-91
pubmed: 2107997
Curr Opin Oncol. 2016 Jul;28(4):323-30
pubmed: 27153355
J Clin Oncol. 2007 Jul 20;25(21):3144-50
pubmed: 17634494
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336

Auteurs

Thomas J Carter (TJ)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Marina Milic (M)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Joanna McDerra (J)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Anne McTiernan (A)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Mahbubl Ahmed (M)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Vasilios Karavasilis (V)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Maria Michelagnoli (M)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Rachael Windsor (R)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Beatrice Seddon (B)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Jeremy Whelan (J)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Palma Dileo (P)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.

Sandra J Strauss (SJ)

London Sarcoma Service, University College London Hospital, Euston Road, London NW1 2PG, UK.
Research Department of Oncology, UCL Cancer Institute, 70 Huntley Street, London WC1E 6BT, UK.

Classifications MeSH